Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

Acta Oncologica

Volumn 44, Issue 7, 2005, Pages 735-741

  Norum, Jan ^a   Holtmon, Mari ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CAPITAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDICAL PRACTICE; MORBIDITY; NORWAY; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DRUG COSTS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MEDICAL RECORDS; METHOTREXATE; NORWAY; SURVIVAL RATE;

EID: 27544458517     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500247503     Document Type: Article

References (29)

1. The World Health Organisation. WHO, [cited 2004 Oct 6]; Available from: URL: http://www.who.int/en/
2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer. The results of 20 years of follow up. N Engl J Med 1995; 332:901-6.
3. Levine M, Bramwell V, Pritchard K, Shepered L. CEF versus CMF in premenopausal women-recent update. Eur J Cancer 1998;34(1):S35.
4. Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer. Is it cost effective? Acta Oncol 2000;39:33-9.
5. Statistics Norway. Statistisk sentralbyrå. [cited 2004 Aug 1]; Available from: URL: http://www.ssb.no.
6. Irvin RJ, Kuhn JG. @Financial considerations in the use of adjuvant chemotherapy. In: Henderson IC, editor. Adjuvant therapy of breast cancer. Kluweer Academic Publishers; 1992. p 207-22.
7. National Insurance Administration. Rikstrygdeverket. [cited 2004 Aug 15]; Available from: URL: http://www.trygdeetaten. no.
8. Kornblith A, Hernon J, Weiss RB, et al. Long-term Adjustment of Survivors of Early-Stage Breast Carcinoma. 20 Years after Adjuvant Chemotherapy. Am Cancer Soc 2003;98: 679-89.
9. Wefel J, Lenzi R, Theriault R, et al. The Cognitive Sequelae of Standard-Dose Adjuvant Chemotherapy in Women with Breast Carcinom. Results of a prospective randomized longitudinal trial. Cancer 2004;11:2292-9.
10. Norwegian Breast Cancer Group. NBCG. Norsk Bryst Cancer Gruppe. [Cited 2004 Aug 1]; Available from: URL: http://www.nbcg.net.
11. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacol Econ 1998;13:1-7.
12. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2002;(1)CD000487.
13. Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21:298-305.
14. Paradiso A, Schittulli F, Cellmare G, et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 2001;19:3929-37.
15. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
16. Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA. 21 study. Oncology 2001;15: 7-13.
17. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrxate and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-10.
18. Bergh J, Jønsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-81.
19. Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow supported high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin or tailored therapy with fluorouacil, epirubicin and cyclophosphamide. J Clin Oncol 2003;21:3659-64.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
21. Del Mastro L, Costantini M, Morasso G, et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer 2000;38:359-66.
22. Murray CJL, Lopez AD. The global burden of disease. Geneva: World Health Organisation; 1996.
23. Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival. Lancet 2001;358:277-86.
24. Jansen SJ, Kievit J, Nooij MA, et al. Patients'preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? Br J Cancer 2001;84:1577-85.
25. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusions. Acta Oncol 2001;40: 135-54.
26. Clifford A. Hudis. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003;4:70-5.
27. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, fluorourrracil chemotherapy compared with cyclophosphamide, methotrxate and fluorouracil in premenopausal women with node-positive breastcancer. J Clin Oncol 1998;16:2651-8.
28. Abrams J S. Adjuvant therapy for Breast Cancer-Results from the USA Consensus Conference. Breast Cancer 2001; 8:298-304.
29. Broet P, Scholl S, Rochefordiere A, et al. Short and long term effects on survival in breastcancer patients treated by primary chemotherapy: An updated analysis of a randomised trial. Br Cancer Res Treat 1999;58:151-6.